Adriana Mihai

Dr. Adriana Mihai

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ALAlina Costina Luca
Alina Costina Luca
SRSolange Tamara V Rosu
Solange Tamara V Rosu
CDCosmin Diaconescu
Cosmin Diaconescu
DMDana Elena Mindru
Dana Elena Mindru
CGCristina Gavrilovici
Cristina Gavrilovici
ELENA TARCAELENA TARCA
ELENA TARCA
The first 1000 days of life, starting from conception to a child’s second birthday, constitute a pivotal period for fetal lung and pulmonary vascular development. Maternal nutrition during this period plays an important role in fetal growth, immune programming and organ development, including that of the pulmonary system. This narrative review consolidates evidence linking maternal nutrition and early-life nutrient intake during this period with the development of pulmonary hypertension in the newborn. We examine the influence of both nutrient deficiencies and excesses on fetal lung and vascular development. We performed a structured search of PubMed and Embase (conducted from February 2025 to March 2025) and screened reference lists. Twenty-eight peer-reviewed studies were included, comprising human clinical and observational evidence and studies on animal models. The findings suggest that imbalances in maternal diet can disrupt placental function, induce inflammation, and trigger epigenetic alterations, all contributing to pulmonary vascular dysfunction and increased pulmonary hypertension susceptibility in neonates. Notably, maternal undernutrition and thiamine deficiency during lactation have been directly linked to pulmonary hypertension in infants. Conversely, high-fat diets and excessive polyphenol intake have been associated with adverse fetal cardiovascular remodeling. While current evidence is primarily derived from animal models and observational studies, it highlights the urgent need for targeted nutritional strategies and clinical trials during pregnancy. Although human causality is unproven for most exposures, studying maternal nutrition in the first 1000 days could offer a cost-effective method for reducing the burden of pediatric pulmonary hypertension and its long-term consequences and for prospective trials aimed at preventing early-life pulmonary vascular disease.

3 June 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
TOTemneanu Oana-Raluca
Temneanu Oana-Raluca
ONOtilia Novac
Otilia Novac
Adriana MihaiAdriana Mihai
Adriana Mihai
FTFelicia Trofin
Felicia Trofin
OFOtilia-Elena Frasinariu
Otilia-Elena Frasinariu
BSBianca Simionescu
Bianca Simionescu
Human milk is widely recognised as the optimal source of nutrition for newborns and infants, providing not only an ideal macronutrient composition but also a range of bioactive components that exert important non-nutritional functions, and as such it represents the first functional food consumed in early life. Among these bioactive components, the human milk oligosaccharides (HMOs)—a structurally diverse family of glycans present in human milk at concentrations 100- to 1000-fold higher than in the milk of other mammalian species—have emerged as multifunctional contributors to the establishment of the intestinal microbiome, immune development, anti-infective defence, and epithelial barrier integrity during a developmental window characterised by immune immaturity. The aim of the present narrative review is to synthesise current evidence on the anti-infective properties of HMOs in infancy and to integrate, within a single framework, five interconnected mechanisms through which HMOs protect the infant against infection: glycan-mimicry-based competitive inhibition of pathogen adhesion, direct antimicrobial and antibiofilm activity, selective prebiotic shaping of the gut microbiome, modulation of innate and adaptive immune responses, and reinforcement of mucosal barrier integrity in the gut and lungs. Breastfeeding constitutes a natural strategy for anti-infective protection in early childhood, while infant formulas supplemented with biotechnologically produced HMOs that are structurally identical to those in human milk provide measurable benefits for non-breastfed infants.

2 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
TOTemneanu Oana-Raluca
Temneanu Oana-Raluca
Adriana MihaiAdriana Mihai
Adriana Mihai
RORaluca OLARIU
Raluca OLARIU
MOMihaela Oros
Mihaela Oros
IIIleana katerina Ioniuc
Ileana katerina Ioniuc
PPPaula Popovici
Paula Popovici
Asthma prevalence in school-age children varies widely by geography, from below 5% in some regions to above 20% in others, averaging 10–12% across industrialized countries, but genetic factors account for less than 40% of disease liability. Gut microbiota is increasingly recognized as a critical intermediary between early-life dietary exposure and immunological trajectories that determine asthma susceptibility. Through the production of short-chain fatty acids (SCFAs), particularly butyrate, propionate, and acetate, commensal bacteria regulate dendritic cell function, promote T-regulatory (Treg) cell differentiation, and attenuate Th2-polarized airway inflammation via the gut–lung axis. Epidemiological cohorts including CHILD, WHEALS, and PASTURE associate early-life dysbiosis and reduced Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii with increased asthma risk, while dietary patterns rich in fermentable fibre, omega-3 polyunsaturated fatty acids, and diverse plant-based foods are associated with preserved microbial diversity and, in preclinical models, attenuated type-2 inflammatory signalling. This narrative review synthesizes mechanistic and epidemiological evidence on how nutritional exposures shape gut microbiota composition and influences asthma onset and severity in paediatric populations, including the distinct obesity-related asthma phenotype. Critical gaps, insufficient dietary intervention trials with microbiome endpoints, methodological heterogeneity across cohorts, and the paucity of data from non-Western populations are discussed, with implications for preventive nutritional counselling in paediatric allergology practice.

19 July 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
OFOtilia-Elena Frasinariu
Otilia-Elena Frasinariu
VȘVioleta Ștreangă
Violeta Ștreangă
ARAniela Luminita Rugină
Aniela Luminita Rugină
DMDana Elena Mindru
Dana Elena Mindru
TVTeodora Cristina Vintilă
Teodora Cristina Vintilă
TDTesoi Dragos
Tesoi Dragos
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disorder in the pediatric population, closely paralleling the global rise in childhood obesity. Increasing evidence highlights the gut–liver axis as a key contributor to MASLD pathogenesis, with gut microbiota dysbiosis influencing hepatic steatosis through multiple interconnected mechanisms, including increased intestinal permeability, endotoxemia, altered bile acid metabolism, and modulation of host energy homeostasis. In children, the characterization of microbiota signatures associated with MASLD remains challenging due to heterogeneity across studies, age-related microbial dynamics, and methodological variability. This review synthesizes current evidence regarding the role of the gut microbiota in pediatric MASLD, focusing on pathogenetic pathways, reported microbial patterns, and microbiota-targeted therapeutic strategies, while incorporating relevant mechanistic evidence from adult studies where pediatric data remain limited. Although several taxa have been repeatedly associated with pediatric MASLD, findings are not yet sufficiently consistent for clinical application. Interventions such as probiotics, prebiotics, and dietary modulation show promising but still preliminary results, with limited high-quality pediatric trials available. A deeper mechanistic understanding and standardized study designs are needed to clarify causality and to support microbiota-based precision approaches in pediatric MASLD management.

29 September 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
TOTemneanu Oana-Raluca
Temneanu Oana-Raluca
LBLaura Bozomitu
Laura Bozomitu
Adriana MihaiAdriana Mihai
Adriana Mihai
AAAndreea Avasiloaiei
Andreea Avasiloaiei
VLVasile Valeriu Lupu
Vasile Valeriu Lupu
IIIleana katerina Ioniuc
Ileana katerina Ioniuc
Childhood obesity now affects more than 160 million children and adolescents worldwide, and over the same period ultra-processed foods have come to dominate the early-life diet. This review sets out a single argument: that the effect of ultra-processed foods on childhood obesity is better read developmentally, and that the digestive tract is the organ through which much of that effect is transmitted. Exposure begins before birth and continues through the first 1000 days and complementary feeding, the period in which the gut microbiota assembles and the intestinal barrier matures. We show how ultra-processed foods perturb these two systems in particular: a low-fibre, additive-rich, energy-dense diet reshapes microbial community structure and depletes short-chain fatty acid production, while emulsifiers and other additives thin the mucus layer and raise intestinal permeability, admitting microbial products that sustain low-grade inflammation. We trace how these gut-level changes feed forward into altered appetite regulation, adipocyte biology and, ultimately, excess adiposity, and we situate the other proposed mechanisms (matrix disruption, hyperpalatability, accelerated eating rate, endocrine-disrupting additives and central reward signalling) around this digestive core, marking at each step where the evidence is paediatric and where it rests on adult or animal data. The epidemiological literature is appraised by study design, and the constraints on causal inference are stated plainly: NOVA misclassification, residual confounding, reverse causation, dietary misreporting and the scarcity of paediatric trials. The practical implication is that prevention framed around early-life gut health, rather than around cumulative adult-style exposure, is where intervention is most plausibly effective. We are explicit throughout that most of the mechanistic evidence derives from animal or adult studies and that a causal role for ultra-processed foods in childhood adiposity, though biologically plausible, is not yet established in paediatric populations; the developmental reading we advance is the most coherent interpretation of an associational evidence base, not a demonstrated causal chain.

25 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Adriana MihaiAdriana Mihai
Adriana Mihai
IIIleana katerina Ioniuc
Ileana katerina Ioniuc
AMAlina Mariela Murgu
Alina Mariela Murgu
ALAncuta Lupu
Ancuta Lupu
OFOtilia-Elena Frasinariu
Otilia-Elena Frasinariu
CGCristina Gavrilovici
Cristina Gavrilovici
Asthma is the most prevalent chronic respiratory disease in childhood, and the objective assessment of airway inflammation remains a major challenge, particularly in younger children in whom conventional lung function testing is often not feasible. The aim of this narrative review is to evaluate the clinical role of fractional exhaled nitric oxide (FeNO) in pediatric asthma, focusing on its diagnostic utility, role in treatment guidance, and value in disease monitoring. A structured literature search was conducted in PubMed for studies published between January 2015 and October 2025, using predefined keywords related to FeNO, asthma, and pediatric populations. After applying the eligibility criteria, 47 studies were included in the final synthesis. Evidence from systematic reviews and clinical studies indicates that FeNO has moderate-to-good diagnostic accuracy for childhood asthma, with a pooled sensitivity of 0.79 and specificity of 0.81, and is most useful as an adjunct to clinical assessment and lung function testing. FeNO-guided therapy may reduce exacerbation rates in selected pediatric populations, although its effects on symptom control and corticosteroid use remain inconsistent. In the monitoring setting, serial FeNO measurements may provide additional information on inflammatory control, treatment adherence, and risk of future exacerbations. However, interpretation is influenced by multiple confounding factors, including atopy, allergic rhinitis, corticosteroid therapy, and asthma phenotype. In conclusion, FeNO is a valuable complementary biomarker in pediatric asthma, with particular utility in improving diagnostic and therapeutic precision. Its optimal use requires careful integration within a multimodal clinical framework rather than reliance as a standalone tool.